share_log

Emergent BioSolutions (NYSE:EBS) Shareholder Returns Have Been Solid, Earning 285% in 1 Year

Emergent BioSolutions (NYSE:EBS) Shareholder Returns Have Been Solid, Earning 285% in 1 Year

Emergent BioSolutions (紐交所:EBS) 股東回報穩健,1年內賺取了285%的收益
Simply Wall St ·  2024/12/31 19:41

When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! For example, the Emergent BioSolutions Inc. (NYSE:EBS) share price had more than doubled in just one year - up 285%. And in the last week the share price has popped 13%. Zooming out, the stock is actually down 81% in the last three years.

當你購買一家公司的股票時,總是有價格跌到零的風險。另一方面,如果你找到一個高質量的業務去買(在合適的價格),你可以賺回超過一倍的錢!例如,Emergent BioSolutions Inc.(紐交所:EBS)的股價在短短一年內就已經翻了一倍,漲幅達285%。而在過去的一週裏,股價上漲了13%。整體來看,過去三年股票實際上下跌了81%。

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

在過去一週強勁上漲後,值得看看長期回報是否是由基本面改善驅動的。

Given that Emergent BioSolutions didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

考慮到Emergent BioSolutions在過去十二個月內沒有盈利,我們將專注於營業收入的增長,以形成對其業務發展的快速看法。一般而言,沒有利潤的公司預計每年都會增長營業收入,並且增長速度良好。正如你所想象的,快速的營業收入增長在維持時,通常會導致快速的利潤增長。

In the last year Emergent BioSolutions saw its revenue grow by 2.0%. That's not great considering the company is losing money. So we wouldn't have expected the share price to rise by 285%. We're happy that investors have made money, though we wonder if the increase will be sustained. It's quite likely that the market is considering other factors, not just revenue growth.

在過去一年中,Emergent BioSolutions的營業收入增長了2.0%。考慮到公司在虧損,這並不理想。因此我們沒料到股價會升高285%。我們很高興投資者獲得了利潤,但我們懷疑這一增長是否會持續。市場可能在考慮其他因素,而不僅僅是營業收入的增長。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下面的圖像中查看收益和營業收入隨時間的變化(點擊圖表查看確切值)。

big
NYSE:EBS Earnings and Revenue Growth December 31st 2024
紐交所:EBS收益和營業收入增長截至2024年12月31日

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

您可以通過這個免費的互動圖形查看其資產負債表隨時間的增強(或減弱)。

A Different Perspective

不同的視角

It's good to see that Emergent BioSolutions has rewarded shareholders with a total shareholder return of 285% in the last twelve months. That certainly beats the loss of about 13% per year over the last half decade. This makes us a little wary, but the business might have turned around its fortunes. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for Emergent BioSolutions that you should be aware of before investing here.

看到Emergent BioSolutions在過去十二個月中爲股東提供了285%的總股東回報,真是讓人高興。這確實超過了過去五年每年約13%的損失。這讓我們有點警惕,但業務可能已經扭轉了局面。我發現從長期來看,股價作爲業務表現的代理非常有趣。但要真正獲得洞察,我們還需要考慮其他信息。例如,我們發現了3個關於Emergent BioSolutions的警告信號,你在投資這裏之前應該了解一下。

We will like Emergent BioSolutions better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.

如果我們看到一些大規模的內部人買入,我們會更喜歡Emergent BioSolutions。在我們等待的同時,請查看這份關於價值被低估的股票(主要是小型股)以及最近內部人買入的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文中引用的市場回報反映了當前在美國交易所上市股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論